Metabolism Assays Market by Product (Instruments, Assays Kits), Technology (Colorimetry, Fluorimetry, Spectrometry), Application (Diagnostics (Diabetes, Obesity), Research), End User (Hospitals, Diagnostic Laboratories), & Region - Global Forecast to 2028
The metabolism assays market is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 7.8% during the forecast period. The growth of this market is majorly driven by the promotion of metabolic research and funding by the government, the growing use of metabolism assays in fitness and sports industry, and an increase in the awareness of early diagnosis. However, issues related high cost of metabolism assays restrain the growth of this market.
“The assay kits & reagents segment accounted for the highest market share in the metabolism assays market, by product, during the forecast period.”
Based on the product segment, the metabolism assays market is classified into instruments & analyzers and assay kits & reagents. In 2022, the assay kits & reagents segment dominated the products market. This segment is also estimated to grow at the highest CAGR during the forecast period. The large share is due to their integration with technologies, such as wearable devices and wide use in diagnostics as it is the major application.
“Pharmaceutical & Biotechnology Companies and CROs & Academic Research Institutes accounted for the highest CAGR during the forecast period.”
Based on end users, the metabolism assays market is segmented into hospitals, diagnostic laboratories, and pharmaceutical & biotechnology companies and CROs & academic research institutes. The pharmaceutical & biotechnology companies and CROs & academic research institutes segment dominated the metabolism assays market in 2022. The diagnostic laboratories segment is expected to grow at the highest CAGR during the forecast period. The large share of this segment can be attributed to increasing R&D investments by pharmaceutical & biotechnology companies on metabolic research.
“The North America segment accounted for the highest market share in the metabolism assays market, by region, during the forecast period.”
Based on the region, the global metabolism assays market is categorized into North America, Europe, Asia Pacific, and Rest of the World. During the forecast period North America is expected to witness a high market share. The presence of robust pharma & biotech industries who are involved in drug discover, toxicity testing & development and the increasing target disease population are supporting the growth of the metabolism assays market. However, Asia Pacific is expected to register highest CAGR during the forecast period.
Breakdown of supply-side primary interviews by company type, designation, and region:
Research Coverage
This research report categorizes the metabolism assays market by product, technology, application, end-user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the metabolism assays market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, services; key strategies; Contracts, partnerships, and agreements. New product & service launches, mergers and acquisitions, and recent developments associated with the metabolism assays market. Competitive analysis of upcoming startups in the metabolism assays market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall metabolism assays market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
“The assay kits & reagents segment accounted for the highest market share in the metabolism assays market, by product, during the forecast period.”
Based on the product segment, the metabolism assays market is classified into instruments & analyzers and assay kits & reagents. In 2022, the assay kits & reagents segment dominated the products market. This segment is also estimated to grow at the highest CAGR during the forecast period. The large share is due to their integration with technologies, such as wearable devices and wide use in diagnostics as it is the major application.
“Pharmaceutical & Biotechnology Companies and CROs & Academic Research Institutes accounted for the highest CAGR during the forecast period.”
Based on end users, the metabolism assays market is segmented into hospitals, diagnostic laboratories, and pharmaceutical & biotechnology companies and CROs & academic research institutes. The pharmaceutical & biotechnology companies and CROs & academic research institutes segment dominated the metabolism assays market in 2022. The diagnostic laboratories segment is expected to grow at the highest CAGR during the forecast period. The large share of this segment can be attributed to increasing R&D investments by pharmaceutical & biotechnology companies on metabolic research.
“The North America segment accounted for the highest market share in the metabolism assays market, by region, during the forecast period.”
Based on the region, the global metabolism assays market is categorized into North America, Europe, Asia Pacific, and Rest of the World. During the forecast period North America is expected to witness a high market share. The presence of robust pharma & biotech industries who are involved in drug discover, toxicity testing & development and the increasing target disease population are supporting the growth of the metabolism assays market. However, Asia Pacific is expected to register highest CAGR during the forecast period.
Breakdown of supply-side primary interviews by company type, designation, and region:
- By Company Type: Tier 1 (30%), Tier 2 (48%), and Tier 3 (22%)
- By Designation: C-level (28%), Director-level (33%), and Others (39%)
- By Region: North America (21%), Asia-Pacific (34%), Europe (30%), and RoW (15%)
Research Coverage
This research report categorizes the metabolism assays market by product, technology, application, end-user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the metabolism assays market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, services; key strategies; Contracts, partnerships, and agreements. New product & service launches, mergers and acquisitions, and recent developments associated with the metabolism assays market. Competitive analysis of upcoming startups in the metabolism assays market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall metabolism assays market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the metabolism assays market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the metabolism assays market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the metabolism assays market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the metabolism assays market
- Competitive Assessment: In-depth assessment of market ranking, growth strategies, and service offerings of leading players like Merck KGaA (Germany), Thermo Fisher (US), Abcam Plc. (UK), and Agilent Technologies Inc. (US), among others in the metabolism assays market strategies.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
TABLE 1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 LIMITATIONS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 METABOLISM ASSAYS MARKET: RESEARCH DESIGN METHODOLOGY
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
TABLE 2 KEY DATA FROM PRIMARY SOURCES
FIGURE 2 KEY INDUSTRY INSIGHTS
2.1.2.1 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 5 BOTTOM-UP APPROACH: REVENUE-BASED APPROACH
2.2.1 GROWTH FORECAST
2.2.2 CAGR PROJECTIONS
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.2.3 TOP-DOWN APPROACH
FIGURE 7 METABOLISM ASSAYS MARKET: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE/RANKING ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 RISK ASSESSMENT
2.7 IMPACT OF RECESSION
3 EXECUTIVE SUMMARY
FIGURE 9 METABOLISM ASSAYS MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION)
FIGURE 10 METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)
FIGURE 11 METABOLISM ASSAYS MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION)
FIGURE 12 METABOLISM ASSAYS MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
FIGURE 13 REGIONAL SNAPSHOT OF METABOLISM ASSAYS MARKET
4 PREMIUM INSIGHTS
4.1 METABOLISM ASSAYS MARKET OVERVIEW
FIGURE 14 INCREASED PREVALENCE OF OBESITY AND DIABETES TO DRIVE METABOLISM ASSAYS MARKET
4.2 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY PRODUCT (2022)
FIGURE 15 ASSAY KITS & REAGENTS ACCOUNTED FOR LARGEST SHARE IN 2022
4.3 REGIONAL GROWTH OPPORTUNITIES IN METABOLISM ASSAYS MARKET
FIGURE 16 GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
4.4 METABOLISM ASSAYS MARKET: REGIONAL MIX
FIGURE 17 ASIA PACIFIC MARKET TO WITNESS FASTEST GROWTH DURING FORECAST PERIOD
4.5 METABOLISM ASSAYS MARKET: DEVELOPED VS. EMERGING ECONOMIES
FIGURE 18 DEVELOPING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN METABOLISM ASSAYS MARKET
5.2.1 DRIVERS
5.2.1.1 Increasing funding and investments in metabolic research
5.2.1.2 Drug discovery and development
5.2.1.3 Rise in prevalence of chronic diseases
5.2.1.4 Increased use of metabolism assays in fitness and sports
5.2.1.5 Growing demand for personalized medicines
5.2.2 RESTRAINTS
5.2.2.1 High cost of metabolism assay analyzers
5.2.2.2 Presence of alternative methods and techniques
5.2.3 OPPORTUNITIES
5.2.3.1 Integration with wearable devices
5.2.3.2 Growing life science research in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Complexity of assay development
5.3 PRICING ANALYSIS
TABLE 3 AVERAGE SELLING PRICE OF PRODUCT, BY KEY PLAYERS
5.4 PATENT ANALYSIS
FIGURE 20 PATENT ANALYSIS FOR METABOLISM ASSAYS (JANUARY 2013–DECEMBER 2022)
5.4.1 LIST OF KEY PATENTS
5.5 VALUE CHAIN ANALYSIS
FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDITION DURING MANUFACTURING & ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 22 METABOLISM ASSAYS MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
FIGURE 23 METABOLISM ASSAYS MARKET: ECOSYSTEM ANALYSIS
5.7.1 METABOLISM ASSAYS MARKET: ROLE IN ECOSYSTEM
FIGURE 24 KEY PLAYERS IN METABOLISM ASSAYS MARKET
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 PORTER’S FIVE FORCES ANALYSIS: METABOLISM ASSAYS MARKET
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF SUPPLIERS
5.8.4 BARGAINING POWER OF BUYERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 REGULATORY ANALYSIS
5.9.1 NORTH AMERICA
5.9.1.1 US
TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION
5.9.1.2 Canada
TABLE 6 CANADA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.9.2 EUROPE
5.9.3 ASIA PACIFIC
5.9.3.1 Japan
TABLE 7 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
5.9.3.2 China
TABLE 8 CHINA: CLASSIFICATION OF MEDICAL DEVICES
5.9.3.3 India
5.10 TRADE ANALYSIS
TABLE 9 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS ON A BACKING, PREPARED DIAGNOSTIC OR LABORATORY REAGENTS WHETHER OR NOT ON A BACKING, AND CERTIFIED REFERENCE MATERIALS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 10 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS ON A BACKING, PREPARED DIAGNOSTIC OR LABORATORY REAGENTS WHETHER OR NOT ON A BACKING, AND CERTIFIED REFERENCE MATERIALS, BY COUNTRY, 2018–2022 (USD MILLION)
5.11 TECHNOLOGY ANALYSIS
5.12 KEY CONFERENCES AND EVENTS IN 2023–2024
TABLE 11 METABOLISM ASSAYS MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, 2023–2024
5.13 TRENDS/DISRUPTIONS IMPACTING BUSINESSES
5.13.1 REVENUE SHIFT IN METABOLISM ASSAYS
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF METABOLISM ASSAYS
TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF METABOLISM ASSAYS
5.14.2 BUYING CRITERIA
FIGURE 26 KEY BUYING CRITERIA FOR METABOLISM ASSAYS
TABLE 13 KEY BUYING CRITERIA FOR METABOLISM ASSAYS
6 METABOLISM ASSAYS MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 14 METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 ASSAY KITS & REAGENTS
6.2.1 COST-EFFECTIVENESS TO INCREASE ADOPTION IN DRUG DISCOVERY
TABLE 15 ASSAY KITS AVAILABLE IN MARKET
TABLE 16 METABOLISM ASSAYS MARKET: ASSAY KITS & REAGENTS, BY REGION, 2021–2028 (USD MILLION)
6.3 INSTRUMENTS & ANALYZERS
6.3.1 AUTOMATION IN INSTRUMENTS, ALONG WITH ADOPTION OF SOFTWARE, TO DRIVE SEGMENTAL GROWTH
TABLE 17 INSTRUMENTS & ANALYZERS AVAILABLE IN MARKET
TABLE 18 METABOLISM ASSAYS MARKET: INSTRUMENTS & ANALYZERS, BY REGION, 2021–2028 (USD MILLION)
7 METABOLISM ASSAYS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 19 METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
7.2 COLORIMETRY
7.2.1 COST-EFFECTIVENESS TO DRIVE MARKET
TABLE 20 METABOLISM ASSAYS MARKET FOR COLORIMETRY, BY REGION, 2021–2028 (USD MILLION)
7.3 FLUORIMETRY
7.3.1 HIGH SENSITIVITY AND SPECIFICITY TO DRIVE MARKET
TABLE 21 METABOLISM ASSAYS MARKET FOR FLUORIMETRY, BY REGION, 2021–2028 (USD MILLION)
7.4 SPECTROMETRY
7.4.1 INCREASED IMPORTANCE IN RESEARCH AND CLINICAL DIAGNOSTICS TO DRIVE MARKET
TABLE 22 METABOLISM ASSAYS MARKET FOR SPECTROMETRY, BY REGION, 2021–2028 (USD MILLION)
8 METABOLISM ASSAYS MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 23 METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
8.2 DIAGNOSTICS
8.2.1 GROWING PREVALENCE OF METABOLIC AND CHRONIC DISEASES TO DRIVE MARKET
TABLE 24 DIAGNOSTICS: METABOLISM ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 25 METABOLISM ASSAYS MARKET FOR DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
8.2.2 DIABETES
TABLE 26 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR DIABETES, BY REGION, 2021–2028 (USD MILLION)
8.2.3 OBESITY
TABLE 27 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR OBESITY, BY REGION, 2021–2028 (USD MILLION)
8.2.4 CANCER
TABLE 28 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION)
8.2.5 CARDIOVASCULAR DISEASES
TABLE 29 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION)
8.2.6 OTHER DIAGNOSTICS
TABLE 30 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR OTHER DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
8.3 RESEARCH
8.3.1 INCREASE IN AWARENESS OF METABOLISM ASSAY IN DISEASE RESEARCH
TABLE 31 RESEARCH: METABOLISM ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION)
9 METABOLISM ASSAYS MARKET, BY END USER
9.1 INTRODUCTION
TABLE 32 METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2 HOSPITALS
9.2.1 AFFORDABILITY AND CONVENIENCE TO DRIVE SEGMENT
TABLE 33 METABOLISM ASSAYS MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
9.3 DIAGNOSTIC LABORATORIES
9.3.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR REDUCTION IN COSTS TO DRIVE MARKET
TABLE 34 METABOLISM ASSAYS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS & ACADEMIC RESEARCH INSTITUTES
9.4.1 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
TABLE 35 METABOLISM ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS & ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
10 METABOLISM ASSAYS MARKET, BY REGION
10.1 INTRODUCTION
TABLE 36 METABOLISM ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 27 NORTH AMERICA: METABOLISM ASSAYS MARKET SNAPSHOT
TABLE 37 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 38 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 39 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 40 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 41 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.1 RECESSION IMPACT
10.2.2 US
10.2.2.1 High rate of drug discovery and toxicity testing to drive market
TABLE 42 US: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 43 US: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 44 US: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 45 US: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.3 CANADA
10.2.3.1 High prevalence of obesity to fuel market growth
TABLE 46 CANADA: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 47 CANADA: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 48 CANADA: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 49 CANADA: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3 EUROPE
TABLE 50 EUROPE: METABOLISM ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 EUROPE: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 52 EUROPE: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 53 EUROPE: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 54 EUROPE: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.1 RECESSION IMPACT
10.3.2 GERMANY
10.3.2.1 Growth of pharmaceutical companies to drive market
TABLE 55 GERMANY: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 56 GERMANY: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 57 GERMANY: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 58 GERMANY: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.3 UK
10.3.3.1 Growing cancer research funding to drive market
TABLE 59 UK: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 60 UK: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 61 UK: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 62 UK: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Rising obese population and prevalence of metabolic disorders to drive market
TABLE 63 FRANCE: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 64 FRANCE: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 65 FRANCE: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 66 FRANCE: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Increasing prevalence of aging population and diabetes to drive market
TABLE 67 SPAIN: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 68 SPAIN: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 69 SPAIN: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 70 SPAIN: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.6 ITALY
10.3.6.1 Growth of pharmaceutical industry to boost market
TABLE 71 ITALY: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 72 ITALY: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 73 ITALY: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 74 ITALY: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 75 REST OF EUROPE: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 76 REST OF EUROPE: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 77 REST OF EUROPE: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 78 REST OF EUROPE: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 28 ASIA PACIFIC: METABOLISM ASSAYS MARKET SNAPSHOT
10.4.1 RECESSION IMPACT
TABLE 79 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 80 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 81 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 82 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 83 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Government initiatives to drive market
TABLE 84 JAPAN: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 85 JAPAN: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 86 JAPAN: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 87 JAPAN: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.3 CHINA
10.4.3.1 Increasing health awareness to drive demand
TABLE 88 CHINA: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 89 CHINA: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 90 CHINA: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 91 CHINA: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Prevalence of chronic diseases to fuel demand
TABLE 92 INDIA: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 93 INDIA: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 94 INDIA: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 95 INDIA: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.5 REST OF ASIA PACIFIC
TABLE 96 REST OF ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 97 REST OF ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 98 REST OF ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 99 REST OF ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5 REST OF THE WORLD
10.5.1 RECESSION IMPACT
TABLE 100 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 101 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 102 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 103 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
TABLE 104 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 29 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN METABOLISM ASSAYS MARKET
11.4 MARKET RANKING ANALYSIS
FIGURE 30 METABOLISM ASSAYS MARKET RANKING ANALYSIS, BY KEY PLAYER (2022)
11.5 COMPANY EVALUATION QUADRANT (2022)
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 31 METABOLISM ASSAYS MARKET: COMPANY EVALUATION QUADRANT FOR KEY PLAYERS, 2022
11.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2022)
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 32 METABOLISM ASSAY MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2022
11.7 COMPETITIVE BENCHMARKING
TABLE 105 METABOLISM ASSAYS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 106 PRODUCT FOOTPRINT OF KEY PLAYERS
TABLE 107 REGIONAL FOOTPRINT OF KEY PLAYERS
TABLE 108 METABOLISM ASSAYS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
11.8 COMPETITIVE SCENARIO
11.8.1 PRODUCT LAUNCHES
TABLE 109 PRODUCT LAUNCHES, JANUARY 2020–AUGUST 2023
11.8.2 DEALS
TABLE 110 DEALS, JANUARY 2020–AUGUST 2023
11.8.3 OTHER DEVELOPMENTS
TABLE 111 OTHER DEVELOPMENTS, JANUARY 2020–AUGUST 2023
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 THERMO FISHER SCIENTIFIC INC.
TABLE 112 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 33 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
12.1.2 MERCK KGAA
TABLE 113 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 34 MERCK KGAA: COMPANY SNAPSHOT (2022)
12.1.3 ABCAM PLC.
TABLE 114 ABCAM PLC.: BUSINESS OVERVIEW
FIGURE 35 ABCAM PLC.: COMPANY SNAPSHOT (2022)
TABLE 115 ABCAM PLC.: DEALS
12.1.4 AGILENT TECHNOLOGIES INC.
TABLE 116 AGILENT TECHNOLOGIES INC.: BUSINESS OVERVIEW
FIGURE 36 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2022)
TABLE 117 AGILENT TECHNOLOGIES INC.: PRODUCT LAUNCHES
12.1.5 KANEKA EUROGENTEC S.A.
TABLE 118 KANEKA EUROGENTEC S.A.: BUSINESS OVERVIEW
FIGURE 37 KANEKA EUROGENTEC S.A.: COMPANY SNAPSHOT (2022)
12.1.6 SARTORIUS AG
TABLE 119 SARTORIUS AG: BUSINESS OVERVIEW
FIGURE 38 SARTORIUS AG: COMPANY SNAPSHOT (2022)
TABLE 120 SARTORIUS AG: PRODUCT LAUNCHES
12.1.7 PROMEGA CORPORATION
TABLE 121 PROMEGA CORPORATION: BUSINESS OVERVIEW
12.1.8 ELABSCIENCE BIOTECHNOLOGY INC.
TABLE 122 ELABSCIENCE BIOTECHNOLOGY INC.: BUSINESS OVERVIEW
12.1.9 RAYBIOTECH LIFE, INC.
TABLE 123 RAYBIOTECH LIFE, INC.: BUSINESS OVERVIEW
12.1.10 BMG LABTECH
TABLE 124 BMG LABTECH: BUSINESS OVERVIEW
TABLE 125 BMG LABTECH: PRODUCT LAUNCHES
12.1.11 BIOTREND CHEMIKALIEN GMBH
TABLE 126 BIOTREND CHEMIKALIEN GMBH: BUSINESS OVERVIEW
12.2 OTHER PLAYERS
12.2.1 3H BIOMEDICAL AB
12.2.2 BIOASSAY SYSTEMS
12.2.3 EMELCA BIOSCIENCE
12.2.4 CREATIVE BIOARRAY
12.2.5 TEMPO BIOSCIENCE, INC.
12.2.6 NCARDIA
12.2.7 NOVOCIB
12.2.8 ETON BIOSCIENCE, INC.
12.2.9 CAYMAN CHEMICAL COMPANY
12.2.10 ENZO LIFE SCIENCES, INC.
12.2.11 ABNOVA CORPORATION
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
TABLE 1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 LIMITATIONS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 METABOLISM ASSAYS MARKET: RESEARCH DESIGN METHODOLOGY
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
TABLE 2 KEY DATA FROM PRIMARY SOURCES
FIGURE 2 KEY INDUSTRY INSIGHTS
2.1.2.1 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 5 BOTTOM-UP APPROACH: REVENUE-BASED APPROACH
2.2.1 GROWTH FORECAST
2.2.2 CAGR PROJECTIONS
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.2.3 TOP-DOWN APPROACH
FIGURE 7 METABOLISM ASSAYS MARKET: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE/RANKING ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 RISK ASSESSMENT
2.7 IMPACT OF RECESSION
3 EXECUTIVE SUMMARY
FIGURE 9 METABOLISM ASSAYS MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION)
FIGURE 10 METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)
FIGURE 11 METABOLISM ASSAYS MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION)
FIGURE 12 METABOLISM ASSAYS MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
FIGURE 13 REGIONAL SNAPSHOT OF METABOLISM ASSAYS MARKET
4 PREMIUM INSIGHTS
4.1 METABOLISM ASSAYS MARKET OVERVIEW
FIGURE 14 INCREASED PREVALENCE OF OBESITY AND DIABETES TO DRIVE METABOLISM ASSAYS MARKET
4.2 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY PRODUCT (2022)
FIGURE 15 ASSAY KITS & REAGENTS ACCOUNTED FOR LARGEST SHARE IN 2022
4.3 REGIONAL GROWTH OPPORTUNITIES IN METABOLISM ASSAYS MARKET
FIGURE 16 GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
4.4 METABOLISM ASSAYS MARKET: REGIONAL MIX
FIGURE 17 ASIA PACIFIC MARKET TO WITNESS FASTEST GROWTH DURING FORECAST PERIOD
4.5 METABOLISM ASSAYS MARKET: DEVELOPED VS. EMERGING ECONOMIES
FIGURE 18 DEVELOPING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN METABOLISM ASSAYS MARKET
5.2.1 DRIVERS
5.2.1.1 Increasing funding and investments in metabolic research
5.2.1.2 Drug discovery and development
5.2.1.3 Rise in prevalence of chronic diseases
5.2.1.4 Increased use of metabolism assays in fitness and sports
5.2.1.5 Growing demand for personalized medicines
5.2.2 RESTRAINTS
5.2.2.1 High cost of metabolism assay analyzers
5.2.2.2 Presence of alternative methods and techniques
5.2.3 OPPORTUNITIES
5.2.3.1 Integration with wearable devices
5.2.3.2 Growing life science research in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Complexity of assay development
5.3 PRICING ANALYSIS
TABLE 3 AVERAGE SELLING PRICE OF PRODUCT, BY KEY PLAYERS
5.4 PATENT ANALYSIS
FIGURE 20 PATENT ANALYSIS FOR METABOLISM ASSAYS (JANUARY 2013–DECEMBER 2022)
5.4.1 LIST OF KEY PATENTS
5.5 VALUE CHAIN ANALYSIS
FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDITION DURING MANUFACTURING & ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 22 METABOLISM ASSAYS MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
FIGURE 23 METABOLISM ASSAYS MARKET: ECOSYSTEM ANALYSIS
5.7.1 METABOLISM ASSAYS MARKET: ROLE IN ECOSYSTEM
FIGURE 24 KEY PLAYERS IN METABOLISM ASSAYS MARKET
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 PORTER’S FIVE FORCES ANALYSIS: METABOLISM ASSAYS MARKET
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF SUPPLIERS
5.8.4 BARGAINING POWER OF BUYERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 REGULATORY ANALYSIS
5.9.1 NORTH AMERICA
5.9.1.1 US
TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION
5.9.1.2 Canada
TABLE 6 CANADA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.9.2 EUROPE
5.9.3 ASIA PACIFIC
5.9.3.1 Japan
TABLE 7 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
5.9.3.2 China
TABLE 8 CHINA: CLASSIFICATION OF MEDICAL DEVICES
5.9.3.3 India
5.10 TRADE ANALYSIS
TABLE 9 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS ON A BACKING, PREPARED DIAGNOSTIC OR LABORATORY REAGENTS WHETHER OR NOT ON A BACKING, AND CERTIFIED REFERENCE MATERIALS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 10 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS ON A BACKING, PREPARED DIAGNOSTIC OR LABORATORY REAGENTS WHETHER OR NOT ON A BACKING, AND CERTIFIED REFERENCE MATERIALS, BY COUNTRY, 2018–2022 (USD MILLION)
5.11 TECHNOLOGY ANALYSIS
5.12 KEY CONFERENCES AND EVENTS IN 2023–2024
TABLE 11 METABOLISM ASSAYS MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, 2023–2024
5.13 TRENDS/DISRUPTIONS IMPACTING BUSINESSES
5.13.1 REVENUE SHIFT IN METABOLISM ASSAYS
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF METABOLISM ASSAYS
TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF METABOLISM ASSAYS
5.14.2 BUYING CRITERIA
FIGURE 26 KEY BUYING CRITERIA FOR METABOLISM ASSAYS
TABLE 13 KEY BUYING CRITERIA FOR METABOLISM ASSAYS
6 METABOLISM ASSAYS MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 14 METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 ASSAY KITS & REAGENTS
6.2.1 COST-EFFECTIVENESS TO INCREASE ADOPTION IN DRUG DISCOVERY
TABLE 15 ASSAY KITS AVAILABLE IN MARKET
TABLE 16 METABOLISM ASSAYS MARKET: ASSAY KITS & REAGENTS, BY REGION, 2021–2028 (USD MILLION)
6.3 INSTRUMENTS & ANALYZERS
6.3.1 AUTOMATION IN INSTRUMENTS, ALONG WITH ADOPTION OF SOFTWARE, TO DRIVE SEGMENTAL GROWTH
TABLE 17 INSTRUMENTS & ANALYZERS AVAILABLE IN MARKET
TABLE 18 METABOLISM ASSAYS MARKET: INSTRUMENTS & ANALYZERS, BY REGION, 2021–2028 (USD MILLION)
7 METABOLISM ASSAYS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 19 METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
7.2 COLORIMETRY
7.2.1 COST-EFFECTIVENESS TO DRIVE MARKET
TABLE 20 METABOLISM ASSAYS MARKET FOR COLORIMETRY, BY REGION, 2021–2028 (USD MILLION)
7.3 FLUORIMETRY
7.3.1 HIGH SENSITIVITY AND SPECIFICITY TO DRIVE MARKET
TABLE 21 METABOLISM ASSAYS MARKET FOR FLUORIMETRY, BY REGION, 2021–2028 (USD MILLION)
7.4 SPECTROMETRY
7.4.1 INCREASED IMPORTANCE IN RESEARCH AND CLINICAL DIAGNOSTICS TO DRIVE MARKET
TABLE 22 METABOLISM ASSAYS MARKET FOR SPECTROMETRY, BY REGION, 2021–2028 (USD MILLION)
8 METABOLISM ASSAYS MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 23 METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
8.2 DIAGNOSTICS
8.2.1 GROWING PREVALENCE OF METABOLIC AND CHRONIC DISEASES TO DRIVE MARKET
TABLE 24 DIAGNOSTICS: METABOLISM ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 25 METABOLISM ASSAYS MARKET FOR DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
8.2.2 DIABETES
TABLE 26 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR DIABETES, BY REGION, 2021–2028 (USD MILLION)
8.2.3 OBESITY
TABLE 27 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR OBESITY, BY REGION, 2021–2028 (USD MILLION)
8.2.4 CANCER
TABLE 28 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION)
8.2.5 CARDIOVASCULAR DISEASES
TABLE 29 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION)
8.2.6 OTHER DIAGNOSTICS
TABLE 30 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR OTHER DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
8.3 RESEARCH
8.3.1 INCREASE IN AWARENESS OF METABOLISM ASSAY IN DISEASE RESEARCH
TABLE 31 RESEARCH: METABOLISM ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION)
9 METABOLISM ASSAYS MARKET, BY END USER
9.1 INTRODUCTION
TABLE 32 METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2 HOSPITALS
9.2.1 AFFORDABILITY AND CONVENIENCE TO DRIVE SEGMENT
TABLE 33 METABOLISM ASSAYS MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
9.3 DIAGNOSTIC LABORATORIES
9.3.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR REDUCTION IN COSTS TO DRIVE MARKET
TABLE 34 METABOLISM ASSAYS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS & ACADEMIC RESEARCH INSTITUTES
9.4.1 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
TABLE 35 METABOLISM ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS & ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
10 METABOLISM ASSAYS MARKET, BY REGION
10.1 INTRODUCTION
TABLE 36 METABOLISM ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 27 NORTH AMERICA: METABOLISM ASSAYS MARKET SNAPSHOT
TABLE 37 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 38 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 39 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 40 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 41 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.1 RECESSION IMPACT
10.2.2 US
10.2.2.1 High rate of drug discovery and toxicity testing to drive market
TABLE 42 US: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 43 US: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 44 US: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 45 US: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.3 CANADA
10.2.3.1 High prevalence of obesity to fuel market growth
TABLE 46 CANADA: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 47 CANADA: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 48 CANADA: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 49 CANADA: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3 EUROPE
TABLE 50 EUROPE: METABOLISM ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 EUROPE: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 52 EUROPE: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 53 EUROPE: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 54 EUROPE: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.1 RECESSION IMPACT
10.3.2 GERMANY
10.3.2.1 Growth of pharmaceutical companies to drive market
TABLE 55 GERMANY: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 56 GERMANY: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 57 GERMANY: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 58 GERMANY: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.3 UK
10.3.3.1 Growing cancer research funding to drive market
TABLE 59 UK: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 60 UK: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 61 UK: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 62 UK: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Rising obese population and prevalence of metabolic disorders to drive market
TABLE 63 FRANCE: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 64 FRANCE: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 65 FRANCE: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 66 FRANCE: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Increasing prevalence of aging population and diabetes to drive market
TABLE 67 SPAIN: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 68 SPAIN: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 69 SPAIN: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 70 SPAIN: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.6 ITALY
10.3.6.1 Growth of pharmaceutical industry to boost market
TABLE 71 ITALY: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 72 ITALY: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 73 ITALY: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 74 ITALY: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 75 REST OF EUROPE: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 76 REST OF EUROPE: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 77 REST OF EUROPE: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 78 REST OF EUROPE: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 28 ASIA PACIFIC: METABOLISM ASSAYS MARKET SNAPSHOT
10.4.1 RECESSION IMPACT
TABLE 79 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 80 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 81 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 82 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 83 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Government initiatives to drive market
TABLE 84 JAPAN: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 85 JAPAN: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 86 JAPAN: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 87 JAPAN: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.3 CHINA
10.4.3.1 Increasing health awareness to drive demand
TABLE 88 CHINA: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 89 CHINA: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 90 CHINA: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 91 CHINA: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Prevalence of chronic diseases to fuel demand
TABLE 92 INDIA: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 93 INDIA: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 94 INDIA: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 95 INDIA: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.5 REST OF ASIA PACIFIC
TABLE 96 REST OF ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 97 REST OF ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 98 REST OF ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 99 REST OF ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5 REST OF THE WORLD
10.5.1 RECESSION IMPACT
TABLE 100 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 101 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 102 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 103 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY END USER, 2021–2028 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
TABLE 104 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 29 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN METABOLISM ASSAYS MARKET
11.4 MARKET RANKING ANALYSIS
FIGURE 30 METABOLISM ASSAYS MARKET RANKING ANALYSIS, BY KEY PLAYER (2022)
11.5 COMPANY EVALUATION QUADRANT (2022)
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 31 METABOLISM ASSAYS MARKET: COMPANY EVALUATION QUADRANT FOR KEY PLAYERS, 2022
11.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2022)
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 32 METABOLISM ASSAY MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2022
11.7 COMPETITIVE BENCHMARKING
TABLE 105 METABOLISM ASSAYS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 106 PRODUCT FOOTPRINT OF KEY PLAYERS
TABLE 107 REGIONAL FOOTPRINT OF KEY PLAYERS
TABLE 108 METABOLISM ASSAYS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
11.8 COMPETITIVE SCENARIO
11.8.1 PRODUCT LAUNCHES
TABLE 109 PRODUCT LAUNCHES, JANUARY 2020–AUGUST 2023
11.8.2 DEALS
TABLE 110 DEALS, JANUARY 2020–AUGUST 2023
11.8.3 OTHER DEVELOPMENTS
TABLE 111 OTHER DEVELOPMENTS, JANUARY 2020–AUGUST 2023
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 THERMO FISHER SCIENTIFIC INC.
TABLE 112 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 33 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
12.1.2 MERCK KGAA
TABLE 113 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 34 MERCK KGAA: COMPANY SNAPSHOT (2022)
12.1.3 ABCAM PLC.
TABLE 114 ABCAM PLC.: BUSINESS OVERVIEW
FIGURE 35 ABCAM PLC.: COMPANY SNAPSHOT (2022)
TABLE 115 ABCAM PLC.: DEALS
12.1.4 AGILENT TECHNOLOGIES INC.
TABLE 116 AGILENT TECHNOLOGIES INC.: BUSINESS OVERVIEW
FIGURE 36 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2022)
TABLE 117 AGILENT TECHNOLOGIES INC.: PRODUCT LAUNCHES
12.1.5 KANEKA EUROGENTEC S.A.
TABLE 118 KANEKA EUROGENTEC S.A.: BUSINESS OVERVIEW
FIGURE 37 KANEKA EUROGENTEC S.A.: COMPANY SNAPSHOT (2022)
12.1.6 SARTORIUS AG
TABLE 119 SARTORIUS AG: BUSINESS OVERVIEW
FIGURE 38 SARTORIUS AG: COMPANY SNAPSHOT (2022)
TABLE 120 SARTORIUS AG: PRODUCT LAUNCHES
12.1.7 PROMEGA CORPORATION
TABLE 121 PROMEGA CORPORATION: BUSINESS OVERVIEW
12.1.8 ELABSCIENCE BIOTECHNOLOGY INC.
TABLE 122 ELABSCIENCE BIOTECHNOLOGY INC.: BUSINESS OVERVIEW
12.1.9 RAYBIOTECH LIFE, INC.
TABLE 123 RAYBIOTECH LIFE, INC.: BUSINESS OVERVIEW
12.1.10 BMG LABTECH
TABLE 124 BMG LABTECH: BUSINESS OVERVIEW
TABLE 125 BMG LABTECH: PRODUCT LAUNCHES
12.1.11 BIOTREND CHEMIKALIEN GMBH
TABLE 126 BIOTREND CHEMIKALIEN GMBH: BUSINESS OVERVIEW
12.2 OTHER PLAYERS
12.2.1 3H BIOMEDICAL AB
12.2.2 BIOASSAY SYSTEMS
12.2.3 EMELCA BIOSCIENCE
12.2.4 CREATIVE BIOARRAY
12.2.5 TEMPO BIOSCIENCE, INC.
12.2.6 NCARDIA
12.2.7 NOVOCIB
12.2.8 ETON BIOSCIENCE, INC.
12.2.9 CAYMAN CHEMICAL COMPANY
12.2.10 ENZO LIFE SCIENCES, INC.
12.2.11 ABNOVA CORPORATION
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
